1. Home
  2. SRTAW vs ABP Comparison

SRTAW vs ABP Comparison

Compare SRTAW & ABP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SRTAW
  • ABP
  • Stock Information
  • Founded
  • SRTAW N/A
  • ABP 2004
  • Country
  • SRTAW United States
  • ABP United States
  • Employees
  • SRTAW N/A
  • ABP N/A
  • Industry
  • SRTAW
  • ABP Biotechnology: Pharmaceutical Preparations
  • Sector
  • SRTAW
  • ABP Health Care
  • Exchange
  • SRTAW Nasdaq
  • ABP Nasdaq
  • Market Cap
  • SRTAW 16.3M
  • ABP 17.2M
  • IPO Year
  • SRTAW 2019
  • ABP N/A
  • Fundamental
  • Price
  • SRTAW $0.18
  • ABP $0.20
  • Analyst Decision
  • SRTAW
  • ABP Strong Buy
  • Analyst Count
  • SRTAW 0
  • ABP 1
  • Target Price
  • SRTAW N/A
  • ABP $4.00
  • AVG Volume (30 Days)
  • SRTAW N/A
  • ABP 5.0M
  • Earning Date
  • SRTAW N/A
  • ABP 11-18-2025
  • Dividend Yield
  • SRTAW N/A
  • ABP N/A
  • EPS Growth
  • SRTAW N/A
  • ABP N/A
  • EPS
  • SRTAW N/A
  • ABP N/A
  • Revenue
  • SRTAW N/A
  • ABP $183,000.00
  • Revenue This Year
  • SRTAW N/A
  • ABP N/A
  • Revenue Next Year
  • SRTAW N/A
  • ABP N/A
  • P/E Ratio
  • SRTAW N/A
  • ABP N/A
  • Revenue Growth
  • SRTAW N/A
  • ABP 154.17
  • 52 Week Low
  • SRTAW N/A
  • ABP $0.15
  • 52 Week High
  • SRTAW N/A
  • ABP $11.19
  • Technical
  • Relative Strength Index (RSI)
  • SRTAW N/A
  • ABP 43.31
  • Support Level
  • SRTAW N/A
  • ABP $0.19
  • Resistance Level
  • SRTAW N/A
  • ABP $0.28
  • Average True Range (ATR)
  • SRTAW 0.00
  • ABP 0.02
  • MACD
  • SRTAW 0.00
  • ABP -0.00
  • Stochastic Oscillator
  • SRTAW 0.00
  • ABP 12.12

About ABP Abpro Holdings Inc Common Stock

Abpro Holdings Inc is a biotechnology company dedicated to developing next-generation antibody therapeutics with the goal of improving the lives of patients with severe and life-threatening diseases. It is focused on novel antibody constructs for immuno-oncology and ophthalmology. By leveraging its proprietary DiversImmune and MultiMabTM antibody discovery and engineering platforms. The company is developing a pipeline of next-generation antibodies, both independently and through collaborations with pharmaceutical and research institutions.

Share on Social Networks: